Regeneus Revenue and Competitors
Estimated Revenue & Valuation
- Regeneus's estimated annual revenue is currently $2M per year.
- Regeneus's estimated revenue per employee is $155,000
Employee Data
- Regeneus has 13 Employees.
- Regeneus grew their employee count by -24% last year.
Regeneus's People
Name | Title | Email/Phone |
---|
Regeneus Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Regeneus?
Regeneus Ltd (ASX: RGS) is a clinical-stage biotech company developing innovative first-in-class stem cell, exosome and immuno-oncology therapies that address significant unmet medical needs.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
-24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Regeneus News
2022-04-20 - Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 ...
Mesoblast; Roslin Cells; Regeneus; ReNeuron Group; International Stem Cell Corporation; Takeda. The report explores the regional and country...
2022-04-17 - Canine Stem Cell Therapy Market Analysis, Research Study ...
VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos. Report overview:.
2022-04-17 - Veterinary Vaccine Market Is Booming Worldwide 2022-2028 ...
Veterinary Vaccine Market Is Booming Worldwide 2022-2028 | Aratana Therapeutics, Inc., Regeneus Ltd., Morphogenesis, Inc.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.1M | 44 | N/A | N/A |
#2 | N/A | 77 | 22% | N/A |
#3 | $28.1M | 104 | -2% | N/A |
#4 | $15.5M | 107 | -4% | N/A |
#5 | $18.3M | 112 | -9% | N/A |